Corporate profile

Miraculins was founded by Dr. Phiet Bui and Dr. Albert Friesen as a result of their collective interest in exploring the macromolecular profiles of bodily fluids as evidence of an individual's state of health. The Company began operations in 2002 when scientific and financial resources came together to make their vision a reality.

Miraculins is a research and development company focused on biomarker discovery using its proprietary B.E.S.T Platform™ for the screening and identification of target proteins and peptides related to diseases.

Miraculins is dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products.

Our promise

Miraculins' president and CEO, Christopher J. Moreau, is joined by an experienced executive management team and a distinguished group of research scientists and support staff who are committed to making meaningful contributions in the fight against cancer.

Vision

Miraculins' vision is to save lives through the early detection and diagnosis of cancer.

Mission

We will contribute substantially to the overall diagnosis and treatment of cancer by our leadership in the discovery and development of biomarker diagnostics to improve the information available to physicians and consequently enhance the quality of treatment for cancer patients.